Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Fineline Cube Aug 7, 2026
Company Deals

Biogen Completes $1 Billion Acquisition of RayThera to Bolster Immunology Portfolio with Novel Small-Molecule Pipeline

Fineline Cube Aug 7, 2026
Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Fineline Cube Aug 7, 2026
Company Drug

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Fineline Cube Aug 7, 2026
Company

GenScript’s Legend Biotech Appoints Three New Directors to Board

Fineline Cube Aug 5, 2022

Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) announced that its subsidiary...

Company Drug Legal / IP

Boehringer Ingelheim Wins Patent Infringement Ruling Against HEC Over Trajenta

Fineline Cube Aug 4, 2022

The China National Intellectual Property Administration (CNIPA) has ruled in favor of German pharmaceutical giant...

Company Drug

Zelgen’s Jacktinib Hits Phase IIb Endpoint in Myelofibrosis Study

Fineline Cube Aug 4, 2022

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the successful completion of a pivotal Phase...

Company Medical Device

Wision A.I.’s Polyp Detection Software Secures NMPA Approval for Colonoscopy Use

Fineline Cube Aug 4, 2022

The National Medical Products Administration (NMPA) has approved China-based Wision A.I.’s intestinal polyp electronic colonoscopy...

Company Medical Device

Ethicon’s Hemostatic Granules Win NMPA Approval for Endoscopic Surgery Use

Fineline Cube Aug 4, 2022

The National Medical Products Administration (NMPA) has granted marketing approval to U.S. medical device firm...

Company Deals

Bloomage Biotech Terminates Medytox Pact Over Botox Supply Issues

Fineline Cube Aug 4, 2022

China-based Bloomage Biotech (SHA: 688363) announced that its wholly owned subsidiary, Gentix Limited, has issued...

Company Deals

WuXi Biologics Partners with AstraZeneca for Local Production of Evusheld

Fineline Cube Aug 4, 2022

China-based WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced...

Company Deals

Structure Therapeutics Oversubscribes USD33m on Top of USD100m Series B Round

Fineline Cube Aug 4, 2022

Structure Therapeutics, a Sino-US firm formerly known as ShouTi Inc., announced the oversubscription of USD33...

Company Drug

Ascletis Pharma’s ASC10 Receives IND Approval for COVID-19 Treatment in US and China

Fineline Cube Aug 4, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) has provided updates on the clinical progress of ASC10,...

Company Drug Legal / IP

ProfoundBio Receives FDA Approval for PRO1184, Appoints New CMO

Fineline Cube Aug 4, 2022

China-based macromolecular targeted therapy developer ProfoundBio (Suzhou) Co., Ltd announced that it has received clinical...

Company

AstraZeneca’s H1 2022 Revenues Surge 48%, Led by Oncology and Vaccines

Fineline Cube Aug 4, 2022

UK-based AstraZeneca (AZ, NASDAQ: AZN) released its financial report for H1 2022, showing a 48%...

Company Drug

Lee’s Pharma Completes Enrollment for NVK-002 Myopia Trials in China

Fineline Cube Aug 3, 2022

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced the completion...

Company Drug

Lynk Pharma Gets NMPA Green Light for LNK01004 Atopic Dermatitis Study

Fineline Cube Aug 3, 2022

Hangzhou-based Lynk Pharmaceuticals Co., Ltd announced it has received approval from the National Medical Products...

Company Drug

Sciwind Biosciences’ XW003 Hits Phase II Trial Goals in Type 2 Diabetes Treatment

Fineline Cube Aug 3, 2022

Hangzhou-based biopharma Sciwind Biosciences Co., Ltd announced positive results from a 20-week Phase II trial...

Company Deals

Fosun Pharma’s Proxima AI Raises Over RMB 100M in Strategic Financing

Fineline Cube Aug 3, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary Shanghai Proxima AI Technology...

Company Deals

Taibang Biologic Raises $300M in Post-Privatization Financing Round

Fineline Cube Aug 3, 2022

Taibang Biologic Group (NASDAQ: CBPO), a plasma specialist privatized by Centurium Capital in April 2021,...

Company Deals

Sironax Completes $200 Million Series B Financing for Age-Related Disease Therapies

Fineline Cube Aug 3, 2022

Beijing-based clinical-stage biotechnology company Sironax announced the completion of a $200 million Series B financing...

Company Deals

ImmVira Partners with China Resources Biopharmaceutical on Oncolytic Virus MVR-C5252 for Gliomas

Fineline Cube Aug 3, 2022

China-based biotech company ImmVira has entered into an exclusive partnership with compatriot firm China Resources...

Company Deals

Tus-Pharma to Acquire Sinotau Pharma for RMB 220 Million

Fineline Cube Aug 3, 2022

China-based Tus-Pharmaceutical Group Co., Ltd (SHE: 000590) has announced plans to acquire 100% of Guangdong...

Company Drug

Eli Lilly Files for Baqsimi Approval in China to Treat Severe Hypoglycemia

Fineline Cube Aug 3, 2022

Eli Lilly & Co. (NYSE: LLY) has submitted a market approval application to China’s Center...

Posts pagination

1 … 680 681 682 … 705

Recent updates

  • CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma
  • Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction
  • Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months
  • Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis
  • Westlake Consortium Secures NMPA Approval for Iscartrelvir, Novel Oral 3CLpro Inhibitor for Mild-to-Moderate COVID-19
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Company Drug

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Company Drug

Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.